
Please try another search
Patrys Limited is an Australia-based company, which is engaged in the development of antibody therapies for the treatment of cancer. The Company is engaged in developing the treatment of Glioblastoma (GBM) and Triple Negative Breast Cancer (TNBC). The Company has developed two forms of deoxymab 3E10, including PAX-DX1 and PAT-DX3. Its is also using the PAT-DX1 antibody to deliver nanoparticles carrying therapeutic payloads to the inside of cells. The Company is in the process of the first human clinical trial of PAT-DX1. Its two product candidates, PAT-DX2 and PAT-DX1-NP are under preclinical stage.
Name | Age | Since | Title |
---|---|---|---|
Michael Stork | - | 2007 | Non-Executive Deputy Chairman |
John Douglas Read | - | 2007 | Non-Executive Chairman |
Pamela Klein | 60 | 2016 | Non-Executive Director |
Susan Jones | 55 | 2011 | Non-Executive Director |
James A. Campbell | - | 2014 | MD, CEO & Executive Director |
Allen Ebens | - | 2016 | Member of Scientific Advisory Board |
Peter Ordentlich | 52 | 2020 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review